UT Health San Antonio obtained $64,848,287 in FY19 from the National Institutes of Health, Department of Defense, industry, and philanthropy to support multi-disciplinary research, teaching, and outreach programs.
UT Health San Antonio patented a discovery in protection against traumatic brain injury.
UT Health San Antonio is home to the Biggs Institute for Alzheimer and Neurodegenerative Diseases, dedicated to clinical research on Alzheimer’s.
UT Health is a leader in translational research studies on neurodegenerative diseases. We take research from the lab into clinical settings to understand the disease process in the brain and explore innovative ways to intervene and slow or stop disease.
UT Health San Antonio faculty are collaborating with other scientists in San Antonio on newly funded projects to advance research on aging, cancer, COVID-19 and trauma care.
The San Antonio Medical Foundation awarded six grants totaling more than $1 million to research teams at local health care and bioscience institutions and organizations, including UT Health San Antonio. Each project selected to receive funding involves a UT Health San Antonio researcher.
Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for treating neurodegenerative brain injuries, is mentioned in this MedCity News story. Dr. James Lechleiter, Cell Systems and Anatomy, is the inventor and patent holder on technology licensed to Astrocyte Pharmaceuticals Inc.
Study findings released Tuesday in the Journal of the American Medical Association (JAMA) hold both good news and bad news about transient ischemic attacks (TIAs), which are harbingers of subsequent strokes.